Authors:
JL Benci, B Xu, Y Qiu, TJ Wu, H Dada, C Twyman-Saint Victor, L Cucolo, DSM Lee, KE Pauken, AC Huang, TC Gangadhar, RK Amaravadi, LM Schuchter, MD Feldman, H Ishwaran, RH Vonderheide, A Maity, EJ Wherry, AJ Minn
Journal name: 
Cell
Citation info: 
167(6):1540-1554.e12
Abstract: 
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
DOI: 
http://doi.org/10.1016/j.cell.2016.11.022
E-pub date: 
30 Nov 2016